AbCellera (ABCL) announced the appointment of Sarah Noonberg as Chief Medical Officer. Noonberg brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization. Most recently, she was the Chief Medical Officer of Metagenomi (MGX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera doses first participants in Phase 1 trial of ABCL575
- AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights
- AbCellera price target raised to $7 from $5 at BMO Capital
- AbCellera Biologics Advances Clinical Trials and Revenue Growth
- AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating